Rethinking health priority-setting in Asia: the role of MScHEOR
Asia’s health systems face mounting trade-offs. Faster population ageing, an increasing share of chronic, noncommunicable diseases and tighter public finances are forcing difficult choices about what care to fund. To help meet this challenge, the Saw Swee Hock School of Public Health at the National University of Singapore offers a Master of Science in Health Economics and Outcomes Research (MScHEOR). The programme equips professionals to convert health data and evidence into robust, policy-ready recommendations that balance equity, sustainability and innovation.
Why this moment demands MScHEOR graduates
– Demographic and disease trends: The proportion of older adults in many Asian countries is rising rapidly, while noncommunicable diseases (NCDs) – such as cardiovascular disease, diabetes and cancer – now account for the majority of morbidity and mortality across the region. This shifts demand toward long-term, often high-cost care and chronic disease management.
– Cost pressures amid innovation: Novel therapeutics, especially in oncology and for rare disorders, often deliver substantial clinical benefit but at considerable price. Governments and payers are therefore formalising health technology assessment (HTA) systems and experimenting with value-based purchasing to ensure new innovations are affordable and sustainable.
– Need for analytical capacity: Decision-makers require professionals fluent in health economics, outcomes measurement and real-world data who can turn complex analyses into clear policy choices. MScHEOR fills this gap by combining quantitative rigour with policy-focused training.
Core competencies and applied skills
The MScHEOR blends methodological depth with practical application. Key areas of training include:
– Economic evaluation and affordability assessment: Techniques for cost-effectiveness analysis and budget impact modelling that estimate incremental costs, health gains and fiscal implications at population scale.
– Real-world data analytics: Working with claims, registries and electronic medical records to assess effectiveness, safety and resource use outside trials.
– Decision models and sensitivity testing: Building Markov and discrete-event models, and conducting probabilistic analyses to characterise uncertainty and inform robust decisions.
– Market access strategy and contracting: Preparing reimbursement dossiers, designing price-volume agreements and structuring outcomes-based contracts that tie payments to patient results.
– Policy translation and stakeholder engagement: Presenting technical findings in concise briefs, developing phased implementation plans and facilitating dialogue among clinicians, payers and finance ministries.
A curriculum shaped by regional needs
MScHEOR was developed in active consultation with regional regulators, payers and life sciences firms to reflect the practical realities of Asian health systems. The syllabus emphasises how to adapt international best practices when data are limited, how to critically appraise manufacturer evidence, and how to weigh trade‑offs – for example, between expanding access rapidly versus phasing rollouts to protect short-term budgets.
Hands-on learning: from datasets to decisions
Students translate classroom methods into real-world outputs through sustained partnerships:
– Policy labs and HTA practicums co-created with national assessment bodies and ministries across ASEAN.
– Industry placements with pharmaceutical and medtech teams preparing market access dossiers or piloting outcome-linked payment models.
– Collaborations with hospital networks and insurers to construct capacity and budget models – for instance, projecting critical care needs under surge scenarios or estimating the cost implications of scaling up integrated diabetes services.
– NGO and public-health projects evaluating cost-effectiveness of community screening, vaccination campaigns or telehealth pilots.
Learners use anonymised claims, disease registries and national health accounts; where full datasets are absent they work with synthetic or aggregated data and apply extensive sensitivity analyses. Graduates build tangible portfolios – policy memos, cost-effectiveness reports and stakeholder presentations – many of which have been reviewed by external partners and used to inform pilot programmes.
Tools and technical fluency
Graduates gain hands-on experience with statistical and modelling tools commonly used in the field (for example, R, Python, SQL and health economic modelling platforms), alongside training in evidence appraisal, data governance and ethical use of real-world data. This combination ensures outputs are technically sound and policy-relevant.
Career pathways and regional impact
MScHEOR alumni move into roles that shape access and reimbursement across the public and private sectors:
– National HTA agencies and ministries of health, conducting assessments and informing benefit design.
– Insurers and social health funds, developing payment systems and risk‑adjustment mechanisms.
– Pharmaceutical and medtech market access and health economics teams, building value dossiers and negotiating agreements.
– Consulting firms, digital health startups and multilateral or non‑governmental organisations advising on scale‑up priorities and cost-effectiveness of public health programmes.
Illustrative graduate contributions
– A graduate partnered with a ministry to design a phased eligibility approach for an innovative heart failure therapy: modelling staged uptake by risk group allowed broader access without breaching short‑term budget caps.
– In a collaboration with an insurer, students developed a predictive model to better allocate primary care payments by patient complexity; early pilots recorded reduced avoidable admissions in participating districts.
– Working with a provincial hospital network, trainees created a capacity-costing tool to prioritise capital investments for critical care expansion during an epidemic surge.
How MScHEOR professionals strengthen policy debates
Beyond modelling, graduates are trained to:
– Convert technical evidence into actionable recommendations that reflect political, ethical and fiscal realities.
– Communicate the limits of analyses and the implications of uncertainty, building trust with finance ministries and clinical stakeholders.
– Design phased implementation and monitoring plans – for example, piloting criteria, tracking real-world performance and updating coverage rules based on observed outcomes.
Regional landscape and future outlook
A number of Asian economies – including Thailand, South Korea, Taiwan and Japan – have well-established HTA institutions, while countries such as Indonesia, Vietnam and the Philippines are increasingly formalising assessment pathways and benefit-setting processes. As outcome-linked contracts and evidence-informed purchasing expand, professionals who can integrate clinical evidence, economic evaluation and real-world data will be essential to sustainable decision-making.
Over the next decade, pressures to optimise limited resources while preserving incentives for innovation will intensify. MScHEOR graduates are positioned to lead that transition: advising governments on which interventions yield the greatest health returns per dollar, guiding industry on credible evidence-generation strategies, and crafting reimbursement mechanisms that reward measurable value.
Conclusion
Making transparent, data-driven coverage decisions is central to maintaining equitable and sustainable health systems in Asia as populations age and medical innovation accelerates. The Master of Science in Health Economics and Outcomes Research at the Saw Swee Hock School of Public Health develops the analytical skillset and policy-oriented mindset needed to steer those decisions – preparing professionals who will influence reimbursement, access and priority-setting across the region.